Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Voyager Therapeutics stock in Canada | $4.2

Own Voyager Therapeutics shares in just a few minutes.

Voyager Therapeutics, Inc
NASDAQ: VYGR - USD
BIOTECHNOLOGY
$3.29
+$0.14 (+4.44%)

Voyager Therapeutics is a biotechnology business based in the US. Voyager Therapeutics stocks (VYGR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.83 – an increase of 6.6% over the previous week. Voyager Therapeutics employs 177 staff and has a trailing 12-month revenue of around $159.6 million.

How to buy Voyager Therapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: VYGR in this case.
  5. Research Voyager Therapeutics stocks. The platform should provide the latest information available.
  6. Buy your Voyager Therapeutics stocks. It's that simple.

How has Coronavirus impacted Voyager Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Voyager Therapeutics's stock price has had significant negative movement.

Its last market close was $4.2, which is 67.01% down on its pre-crash value of $12.73 and 49.05% down on the lowest point reached during the March crash when the stocks fell as low as $6.26.

If you had bought $1,000 worth of Voyager Therapeutics stocks at the start of February 2020, those stocks would have been worth $614.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $357.46.

Voyager Therapeutics stock price

Use our graph to track the performance of VYGR stocks over time.

Voyager Therapeutics stocks at a glance

Information last updated 2021-07-30.
Latest market close$4.2
52-week range$3.04 - $12.65
50-day moving average $3.9466
200-day moving average $5.2754
Wall St. target price$9.61
PE ratio 3.0115
Dividend yield N/A (0%)
Earnings per share (TTM) $1.046

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Voyager Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Voyager Therapeutics price performance over time

Historical closes compared with the last close of $4.2

1 month (2021-07-02) 1.94%
3 months (2021-04-30) -12.86%

Is Voyager Therapeutics under- or over-valued?

Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Voyager Therapeutics's P/E ratio

Voyager Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Voyager Therapeutics stocks trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.

Voyager Therapeutics's EBITDA

Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$30.5 million.

The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.

Voyager Therapeutics financials

Revenue TTM USD$159.6 million
Operating margin TTM 16.44%
Gross profit TTM USD$62.4 million
Return on assets TTM 5.85%
Return on equity TTM 36.45%
Profit margin 24.66%
Book value $3.627
Market capitalisation USD$118.8 million

TTM: trailing 12 months

How to short and sell Voyager Therapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "VYGR.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 887,565 Voyager Therapeutics stocks held short by investors – that's known as Voyager Therapeutics's "short interest". This figure is 1.5% up from 874,329 last month.

There are a few different ways that this level of interest in shorting Voyager Therapeutics stocks can be evaluated.

Voyager Therapeutics's "short interest ratio" (SIR)

Voyager Therapeutics's "short interest ratio" (SIR) is the quantity of Voyager Therapeutics stocks currently shorted divided by the average quantity of Voyager Therapeutics stocks traded daily (recently around 558216.98113208). Voyager Therapeutics's SIR currently stands at 1.59. In other words for every 100,000 Voyager Therapeutics stocks traded daily on the market, roughly 1590 stocks are currently held short.

However Voyager Therapeutics's short interest can also be evaluated against the total number of Voyager Therapeutics stocks, or, against the total number of tradable Voyager Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Voyager Therapeutics's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Voyager Therapeutics stocks in existence, roughly 20 stocks are currently held short) or 0.0398% of the tradable stocks (for every 100,000 tradable Voyager Therapeutics stocks, roughly 40 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Voyager Therapeutics.

Find out more about how you can short Voyager Therapeutics stock.

Voyager Therapeutics stock dividends

We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Voyager Therapeutics stock price volatility

Over the last 12 months, Voyager Therapeutics's stocks have ranged in value from as little as $3.04 up to $12.65. A popular way to gauge a stock's volatility is its "beta".

VYGR.US volatility(beta: 1.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.0724. This would suggest that Voyager Therapeutics's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Voyager Therapeutics overview

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Stocks similar to Voyager Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site